274 related articles for article (PubMed ID: 26590797)
1. Modulation of DNA damage response and induction of apoptosis mediates synergism between doxorubicin and a new imidazopyridine derivative in breast and lung cancer cells.
El-Awady RA; Semreen MH; Saber-Ayad MM; Cyprian F; Menon V; Al-Tel TH
DNA Repair (Amst); 2016 Jan; 37():1-11. PubMed ID: 26590797
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
3. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells.
Tun JO; Salvador-Reyes LA; Velarde MC; Saito N; Suwanborirux K; Concepcion GP
Mar Drugs; 2019 Sep; 17(9):. PubMed ID: 31527453
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
[TBL] [Abstract][Full Text] [Related]
6. DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression.
Jun DW; Hwang M; Kim YH; Kim KT; Kim S; Lee CH
Oncotarget; 2016 Apr; 7(14):17699-710. PubMed ID: 26848527
[TBL] [Abstract][Full Text] [Related]
7. A novel carbazole derivative, MHY407, sensitizes cancer cells to doxorubicin-, etoposide-, and radiation treatment via DNA damage.
Yoon S; Kim JH; Lee YJ; Ahn MY; Choi G; Kim WK; Yang Z; Lee HJ; Moon HR; Kim HS
Eur J Pharmacol; 2012 Dec; 697(1-3):24-31. PubMed ID: 23085270
[TBL] [Abstract][Full Text] [Related]
8. Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity.
Inao T; Kotani H; Iida Y; Kartika ID; Okimoto T; Tanino R; Shiba E; Harada M
Cancer Sci; 2019 Sep; 110(9):2690-2699. PubMed ID: 31250942
[TBL] [Abstract][Full Text] [Related]
9. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
Seoane S; Montero JC; Ocaña A; Pandiella A
J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
[TBL] [Abstract][Full Text] [Related]
10. Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy.
Crescenzi E; Palumbo G; Brady HJ
Clin Cancer Res; 2005 Nov; 11(22):8158-71. PubMed ID: 16299248
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
12. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
[TBL] [Abstract][Full Text] [Related]
13. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
[TBL] [Abstract][Full Text] [Related]
14. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
Zhou Y; Pan DS; Shan S; Zhu JZ; Zhang K; Yue XP; Nie LP; Wan J; Lu XP; Zhang W; Ning ZQ
Biomed Pharmacother; 2014 May; 68(4):483-91. PubMed ID: 24721323
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma.
Weng MT; Tung TH; Lee JH; Wei SC; Lin HL; Huang YJ; Wong JM; Luo J; Sheu JC
Sci Rep; 2015 Apr; 5():9357. PubMed ID: 25880358
[TBL] [Abstract][Full Text] [Related]
16. Targeting actin inhibits repair of doxorubicin-induced DNA damage: a novel therapeutic approach for combination therapy.
Pfitzer L; Moser C; Gegenfurtner F; Arner A; Foerster F; Atzberger C; Zisis T; Kubisch-Dohmen R; Busse J; Smith R; Timinszky G; Kalinina OV; Müller R; Wagner E; Vollmar AM; Zahler S
Cell Death Dis; 2019 Apr; 10(4):302. PubMed ID: 30944311
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma.
Mack PC; Gandara DR; Lau AH; Lara PN; Edelman MJ; Gumerlock PH
Cancer Chemother Pharmacol; 2003 Apr; 51(4):337-48. PubMed ID: 12721762
[TBL] [Abstract][Full Text] [Related]
18. Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines.
Engel D; Nudelman A; Levovich I; Gruss-Fischer T; Entin-Meer M; Phillips DR; Cutts SM; Rephaeli A
J Cancer Res Clin Oncol; 2006 Oct; 132(10):673-83. PubMed ID: 16826403
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S
Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated Hsp27 activates ATM-dependent p53 signaling and mediates the resistance of MCF-7 cells to doxorubicin-induced apoptosis.
Xu Y; Diao Y; Qi S; Pan X; Wang Q; Xin Y; Cao X; Ruan J; Zhao Z; Luo L; Liu C; Yin Z
Cell Signal; 2013 May; 25(5):1176-85. PubMed ID: 23357534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]